|
|
|
Consultants are known for methodologies and frameworks like the S-curve, SWOT analysis, product life cycles, and the ubiquitous two-by-two
matrix. When routinely applied, these tools which work exceptionally well in the automotive, information technology, or energy sectors fail
when applied to biotechnology, pharmaceuticals, and medical devices. The inputs are too superficial, the development time frames too long,
and these tools do not properly incorporate FDA and Medicare regulatory influences.
These tools can be valuable in the hands of experienced, industry experts with the judgment to avoid "garbage-in, garbage-out." Whether it
is portfolio prioritization in R&D, Monte Carlo analysis in product forecasting, system economic analysis in drug pricing, or salesforce
alignment in clinical diagnostics, ordinary tools, methodologies, and frameworks need to be modified for use in healthcare.
Our senior leaders are well schooled in functional tools, and they also have years of experience adapting them for use in our industry. Working
with a management team on a SWOT analysis (strengths, weaknesses, threats, and opportunities) is not an exercise in educating the consultants
about your business. Rather it is a constructive, interactive discussion in which we challenge our clients to broaden their vision, to think
out of the box, and to benchmark themselves accurately against competitors.
|
|
 |
|
|
|
|
|
Pricing considerations influence almost every decision.
Prior to launching a novel oncology drug for the first of four indications, our client required a clear strategy to optimize the initial launch price.
 learn more
|
|
|
|
|
 |
|
|
